Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

/emtricitabine to dolutegravir/lamivudine

  • 0 views
  • 25 Jan, 2021
  • 1 location
Risk of SDRs Under 3HP and 1HP Regimen for LTBI

Successful implement of preventive therapy for subjects with latent tuberculosis infection (LTBI) is the critical step for elimination of tuberculosis (TB). The major obstacle of traditional preventive therapy is the unacceptable long treatment duration, taking isoniazid 5mg/kg daily for a total of 9 months (9H), thus seriously compromising its acceptability. …

skin test
rifapentine
smear
pulmonary tuberculosis
isoniazid
  • 0 views
  • 25 Jan, 2021
  • 1 location
Second-line Switch to Dolutegravir Study

investigators will evaluate the efficacy of switching from a PIr to a dolutegravir based second line ART regimen. Hypothesis: switching virologically suppressed patients from a PIr based second line to a

  • 9 views
  • 24 Jan, 2021
  • 4 locations
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir

antiretroviral
antiretroviral agents
HIV Vaccine
antiretroviral therapy
dolutegravir
  • 1172 views
  • 23 Jan, 2021
  • 32 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase

HIV Vaccine
abacavir
hiv-1 rna measurement
integrase inhibitors
immunodeficiency
  • 188 views
  • 29 Dec, 2020
  • 15 locations
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens. Thus, there is great interest from participants and clinicians in unique regimens that might avoid such toxicities by minimizing the …

pre-exposure prophylaxis (prep)
antiretroviral
antiretroviral agents
HIV Vaccine
mother-to-child transmission
  • 16 views
  • 30 Nov, 2020
  • 10 locations
The Pharmacokinetics Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children

antiretroviral agents
antiretroviral therapy
antibody test
atazanavir
hiv-1 rna measurement
  • 30 views
  • 25 Jan, 2021
  • 14 locations
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive HIV-1 and Hepatitis B Co-Infected Adults

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG

  • 459 views
  • 17 Jan, 2021
  • 122 locations
Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)

(EFV) was found reducing the exposure to DP. WHO now recommends dolutegravir (DTG) based combination antiretroviral therapy (ARTs) as the preferred firstline regimen including for pregnant women in the

  • 0 views
  • 23 Jan, 2021
  • 1 location
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …

  • 0 views
  • 25 Jan, 2021
  • 16 locations